Document Type : Letter to Editor


1 Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Emergency Department, Shohadye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran


The coronavirus disease 2019 (COVID-19) was first emerged from Wuhan, China, in late 2019, and has since been spreading progressively all around the world. Its prevalence is climbing increasingly and almost all countries worldwide are confronting this pandemic. As of April 11, 2020, reports obtained about the management of COVID-19 patients indicate that the mortality rate of the disease is around 5% with consideration of the active cases and 21% of the closed cases


Main Subjects

1. World Metrics. COVID-19 coronavirus outbreak. [cited 2020 Mar 17]; Available from:
2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20. doi: 10.1056/NEJMoa2002032.
3. Wang Y, Yao L, Zhang J, Tang P, Ye Z, Shen X, et al. Clinical characteristics and laboratory indicator analysis of 69 COVID-19 pneumonia patients in Suzhou, China. Research Square; 2020. doi: 10.21203/
4. Guo J, Huang Z, Lin L, Lv J. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus2 infection. J Am Heart Assoc 2020; 9(7): e016219. doi: 10.1161/jaha.120.016219.
5. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the
functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203(2):631-7. doi: 10.1002/path.1570.
6. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology 2020; 295(3): 200463. doi: 10.1148/radiol.2020200463.
7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054-62. doi: 10.1016/s0140-6736(20)30566-3.
8. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-7. doi: 10.1016/j.thromres.2020.04.013.
9. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18(4): 844-7. doi:10.1111/jth.14768.
10. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18(5): 1094-9. doi: 10.1111/ jth.14817.
11. Yao Y, Cao J, Wang Q, Liu K, Luo Z, Yu K, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. Research Square; 2020. doi:
12. Zhou Y, Yang Z, Guo Y, Geng S, Gao S, Ye S, et al. A new predictor of disease severity in patients with
COVID-19 in Wuhan, China. medRxiv; 2020. doi: 10.1101/2020.03.24.20042119.
13. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020; 18(6): 1421-4. doi:10.1111/jth.14830.